Ebrahim Jalili1, Salman Khazaei2, Afshin Mohammadi3, Fariba Keramat4, Seyed Hamid Hashemi4, Saeid Bashirian5, Toos Kiani6, Farid Azizi Jalilian7, Samereh Ghelichkhani6, Manoochehr Karami8,9, Maryam Farrokhi10, Rashid Heidarimoghadam11, Tahereh Abbasi Garavand12, Ebrahim Daneshyar6, Mohammad Abbasi12. 1. Department of Emergency Medicine, School of Medicine, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran. 2. Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran. 3. Blood Transfusion Organization, Hamadan, Iran. 4. Brucellosis Research Center, Sina Educational and Medical Center, Hamadan University of Medical Sciences, Hamadan, Iran. 5. Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. 6. Deputy of Treatment, Hamadan University of Medical Sciences, Hamadan, Iran. 7. Department of Virology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. 8. Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. 9. Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 10. Deputy of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran. 11. Health Sciences Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. 12. Department of Internal Medicine, School of Medicine, Shahid Beheshti Medical Educational Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Abstract
Background: Due to the critical condition of COVID-19, it is necessary to evaluate the efficacy of administrating convalescent plasma to COVID-19 patients. Therefore, we decided to design a clinical trial to investigate the effect of convalescent plasma of patients recovered from COVID-19 on the treatment outcome of COVID-19-infected patients. Materials and Methods: In this parallel randomized controlled clinical trial, patients in the intervention group received standard treatment plus convalescent plasma of patients recovered from COVID-19. We allocated 60 patients to each treatment group through balanced block randomization. Then, COVID-19 outcomes, vital signs, and biochemical parameters were compared between the two treatment groups by the independent t test and ANCOVA. Results: The mean age (SD) of the patients in the intervention and standard treatment groups was 52.84 (15.77) and 55.15 (14.34) years, respectively. Although patients in the intervention group reported more hospitalization days (11.45±5.86 vs. 10.42±6.79), death rates (26.67% vs. 18.13%), ICU admission (45 vs. 41.67%), and ARDS (11.67% vs. 3.33%), these differences were not statistically significant (P>0.05). Moreover, the two groups were homogenous in vital signs and biochemical parameters before and after treatment (P>0.05). Conclusion: The present study indicated that convalescent plasma therapy has no significant effect on the survival, hospitalization, and ICU admission of COVID-19 patients. Copyright
Background: Due to the critical condition of COVID-19, it is necessary to evaluate the efficacy of administrating convalescent plasma to COVID-19 patients. Therefore, we decided to design a clinical trial to investigate the effect of convalescent plasma of patients recovered from COVID-19 on the treatment outcome of COVID-19-infected patients. Materials and Methods: In this parallel randomized controlled clinical trial, patients in the intervention group received standard treatment plus convalescent plasma of patients recovered from COVID-19. We allocated 60 patients to each treatment group through balanced block randomization. Then, COVID-19 outcomes, vital signs, and biochemical parameters were compared between the two treatment groups by the independent t test and ANCOVA. Results: The mean age (SD) of the patients in the intervention and standard treatment groups was 52.84 (15.77) and 55.15 (14.34) years, respectively. Although patients in the intervention group reported more hospitalization days (11.45±5.86 vs. 10.42±6.79), death rates (26.67% vs. 18.13%), ICU admission (45 vs. 41.67%), and ARDS (11.67% vs. 3.33%), these differences were not statistically significant (P>0.05). Moreover, the two groups were homogenous in vital signs and biochemical parameters before and after treatment (P>0.05). Conclusion: The present study indicated that convalescent plasma therapy has no significant effect on the survival, hospitalization, and ICU admission of COVID-19 patients. Copyright
Authors: Y Cheng; R Wong; Y O Y Soo; W S Wong; C K Lee; M H L Ng; P Chan; K C Wong; C B Leung; G Cheng Journal: Eur J Clin Microbiol Infect Dis Date: 2005-01 Impact factor: 3.267
Authors: John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Michael J Joyner; Katelyn A Bruno; Stephen A Klassen; Katie L Kunze; Patrick W Johnson; Elizabeth R Lesser; Chad C Wiggins; Jonathon W Senefeld; Allan M Klompas; David O Hodge; John R A Shepherd; Robert F Rea; Emily R Whelan; Andrew J Clayburn; Matthew R Spiegel; Sarah E Baker; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; Matthew R Buras; Matthew N P Vogt; Vitaly Herasevich; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Noud van Helmond; Brian P Butterfield; Matthew A Sexton; Juan C Diaz Soto; Nigel S Paneth; Nicole C Verdun; Peter Marks; Arturo Casadevall; DeLisa Fairweather; Rickey E Carter; R Scott Wright Journal: Mayo Clin Proc Date: 2020-07-19 Impact factor: 7.616